Aerovate signals cash dividend ahead of Jade merger

Published 07/04/2025, 13:38
Aerovate signals cash dividend ahead of Jade merger

WALTHAM, Mass. - Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a biotechnology firm with a current market capitalization of $72.17 million, has indicated plans to issue a cash dividend to its stockholders before its upcoming merger with Jade Biosciences, Inc. The anticipated dividend is expected to be between $67.6 million and $69.6 million in total, contingent on the company’s net cash position at the time of the merger’s completion. According to InvestingPro data, this would mark the company’s first dividend payment, as it has historically not distributed dividends to shareholders.

The official declaration and the exact amount of the cash dividend are pending approval from Aerovate’s board of directors, with an announcement due later this month. The payment of the dividend is set to coincide with the closing of the merger, which is subject to stockholder approval and other customary closing conditions. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 20.93, indicating ample assets to meet its short-term obligations.

Aerovate’s stockholders are scheduled to vote on the merger during a special meeting at 9:00 a.m. ET on April 16, 2025. With all conditions expected to be met, the parties anticipate the merger to finalize by April 30, 2025.

The merger between Aerovate, known for its work in rare cardiopulmonary diseases, and Jade Biosciences, which focuses on autoimmune disease therapies, is seen as a strategic move to combine their expertise and pipelines. Jade’s lead asset, JADE-001, is currently preparing for a first-in-human trial in the latter half of 2025, targeting a cytokine for the treatment of IgA nephropathy.

Aerovate’s announcement comes with the usual caution that forward-looking statements are subject to risks and uncertainties. The company stresses that actual results may vary significantly if certain assumptions prove incorrect or if unforeseen risks materialize.

This disclosure is based on a press release statement and does not constitute an offer to sell securities or a solicitation of an offer to buy. It is intended to provide information to Aerovate’s investors and stockholders regarding the expected cash dividend in connection with the proposed merger with Jade Biosciences. The stock has experienced significant volatility, with InvestingPro data showing a 90% decline over the past year. Investors seeking deeper insights into Aerovate’s financial health metrics and additional analysis can access 8 more exclusive ProTips and comprehensive financial data through InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.